Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02764541 · ClinicalTrials.gov registry record · Phase 2
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
A Phase 2 study of Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 195
- Enrollment target
- 11
- Study locations
NCT02764541 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 195 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 11 study locations across 6 states.
The verdict
NCT02764541, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 195 participants
- Enrollment target
- 11
- Study locations
Study Summary
This research study is evaluating how well Breast Cancer responds to preoperative treatment with Endocrine treatment in combination with a drug called Palbociclib or Endocrine treatment alone as possible treatments for Hormone Receptor Positive Breast Cancer.
Conditions Studied
Interventions
- DRUG Tamoxifen
- DRUG Letrozole
- DRUG Palbociclib
- DRUG Endocrine Therapy
Study Locations (11)
Massachusetts
- Dana-Farber at St. Elizabeth's Medical Center - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
- DF/BWCC at Milford Regional Medical Center - Milford
- DF/BWCC in clinical affiliation with South Shore Hospital - South Weymouth
Tennessee
- Sarah Cannon Research Institute - Nashville
- Vanderbilt University Medical Center - Nashville
Connecticut
- Stamford Hospital - Stamford
Maine
- Eastern Maine Medical Center - Brewer
Rhode Island
- Lifespan - Providence
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2016-05-24 |
| Est. Completion | 2031-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02764541
The ClinicalTrials.gov registry entry for NCT02764541 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Tamoxifen is the first listed.
NCT02764541 reports 11 study locations spanning 6 distinct geographic areas - top geographies include Massachusetts, Tennessee, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02764541 about?
NCT02764541 is a clinical study titled "Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)". This research study is evaluating how well Breast Cancer responds to preoperative treatment with Endocrine treatment in combination with a drug called Palbociclib or Endocrine treatment alone as possible treatments for Hormone Receptor Positive Breast Cancer.
What is the current status of trial NCT02764541?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 195 participants. The study started on 2016-05-24. Estimated completion is 2031-04.
What conditions does trial NCT02764541 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT02764541?
The interventions under investigation include: Tamoxifen (DRUG), Letrozole (DRUG), Palbociclib (DRUG), Endocrine Therapy (DRUG).
Who is sponsoring clinical trial NCT02764541?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02764541 being conducted?
This trial has 11 study locations across Connecticut, Maine, Massachusetts, Rhode Island, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.